menu
    • menu
    [{"orgOrder":0,"company":"Ariceum Therapeutics","sponsor":"Healthcaps India","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Peptide, Unconjugated","year":"2022","type":"Series A Financing","leadProduct":"Satoreotide Tetraxetan","moa":"peptides: inhibition of growth hormone release; chelating agents","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ariceum Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"Ariceum Therapeutics \/ Healthcaps India","highestDevelopmentStatusID":"7","companyTruncated":"Ariceum Therapeutics \/ Healthcaps India"}]

    Find Clinical Drug Pipeline Developments & Deals for Satoreotide Tetraxetan

    Menu

    Satoreotide Tetraxetan

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Ariceum Therapeutics

                            Germany arrow
                            The MedTech Conference
                            Not Confirmed

                            Ariceum Therapeutics

                            Germany arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Satoreotide Tetraxetan

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Healthcaps India

                            Deal Size : $26.4 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Ariceum Therapeutics Launches with EUR 25M Series A to Advance Lead Asset, Satoreotide, for the Treatment of L...

                            Details : The proceeds from the financing will enable Ariceum to further develop its lead asset and proprietary peptide derivative, 177Lu-OPS201 (satoreotide). Satoreotide is a radiopharmaceutical drug and an antagonist of the somatostatin type 2 (SST2) receptor.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Undisclosed

                            June 08, 2022

                            Lead Product(s) : Satoreotide Tetraxetan

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Healthcaps India

                            Deal Size : $26.4 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Ipsen

                            France arrow
                            The MedTech Conference
                            Not Confirmed

                            Ipsen

                            France arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Satoreotide Tetraxetan

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluate the Safety, Tolerability, Biodistribution and Anti Tumour Activity of 177LU-OPS201 With Companion Ima...

                            Details : Satoreotide Tetraxetan is a Peptide drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Small Cell Lung Carcinoma.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            December 12, 2018

                            Lead Product(s) : Satoreotide Tetraxetan

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Ipsen

                            France arrow
                            The MedTech Conference
                            Not Confirmed

                            Ipsen

                            France arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Satoreotide Tetraxetan

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs

                            Details : Satoreotide Tetraxetan is a Peptide drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Neuroendocrine Tumors.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            October 30, 2015

                            Lead Product(s) : Satoreotide Tetraxetan

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth